AgeneBio: Clinical Trials

4 trials sponsored by AgeneBio, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 withdrawn. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Completed 1, Withdrawn 1
Phase 31Completed 1

Follow AgeneBio: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
AGB101, Placebo - Hippocampal Overactivity, Dementia
Phase 2Active not recruitingJohns Hopkins University602025-04-172026-08-31
Clinical Trial of AGB101 for Mild Cognitive Impairment
AGB101, Placebo - Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Phase 2WithdrawnAgeneBio2024-12-032025-05-25
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
AGB101 - Parkinson Disease Psychosis
Phase 2Active not recruitingJohns Hopkins University302023-09-282026-10-07
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
Placebo Oral Tablet, AGB101 220 mg tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Phase 2 / Phase 3CompletedAgeneBio1642018-12-132024-05-17

Conditions studied

Cognitive Dysfunction (2)  ·  Dementia (1)

Interventions

Levetiracetam (3)  ·  Sugars (1)  ·  Tablets (1)

Countries

United States (4)  ·  Canada (1)

Top investigators

Arnold Bakker, Ph.D. (2)  ·  Marilyn Albert, PhD (1)  ·  Richard Mohs, PhD (1)  ·  Russell Barton, MS (1)  ·  Sharon Rosenzweig-Lipson, PhD (1)

NIH funding

R01AG061091 (2), R01AG048349 (1), R56AG055416 (1)